Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04175301 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect H2 Water on QoL of Patients Receiving Radiotherapy for High Grade Gliomas.

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 29, 2025 (before its estimated September 5, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jul 5, 2025 to Sep 5, 2026
    • Study completion date: Aug 31, 2025 to Sep 30, 2027
    v7
  2. Re-verified, no change to tracked fieldsv6
  3. Primary completion date: Dec 31, 2023 to Jul 5, 2025
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v5
  4. Study completion date: Dec 31, 2023 to Aug 31, 2025v4
  5. Primary completion date: Oct 31, 2022 to Dec 31, 2023
    • Study completion date: Oct 31, 2023 to Dec 31, 2023
    v3
  6. Eligibility criteria expanded, about 5 wordsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Stony Brook University
44 trials monitored
See 1 trial at risk
Glioma
1,251 trials monitored
See 88 trials at risk
This is a pilot randomized control trial (RCT) to explore the effects of hydrogen rich water on quality of life in patients with high grade gliomas, receiving focal radiation therapy to the brain concurrent with chemotherapy with Temozolomide.
Trial Details
NCT Number NCT04175301
Lead Sponsor Stony Brook University
Conditions
(from sponsor)		 Malignant Glioma
Related terms Glioma
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov